Dmitry Kaminskiy is an innovative entrepreneur and investor who is active in the fields of BioTech, FinTech, BlockChain and Artificial Intelligence. Kaminskiy is a co-founder and a senior partner at Deep Knowledge Ventures, a Hong Kong based investment fund focused on disruptive exponential technologies, globally known as the first company to appoint Artificial Intelligence VITAL to its board of directors (Validating Investment Tool for Advancing Life Science).
Considering the significant growth of interest in the Longevity industry, Deep Knowledge Life Sciences, a London-based subsidiary investment fund, was incorporated in 2016, which has increasingly expanded its investment activities in this sector and will actively strengthen its portfolio to catch the wave edge of the rising trend “Investing in Longevity”. Insilico Medicine is the flagship among portfolio companies, a leading pioneer at the intersection of AI, personalized medicine and Longevity.
Dmitry adheres to the principal of “Impact Investment” in all his business activities, believing that business should act to have significant impact for social good. He operates according to the maxim that business should not be separated from societal good and humanitarianism, and his activities in both business and the non-profit sector are aimed at the shared goal of advancing exponential and disruptive technologies to accelerate positive paradigm shifts in finance, healthcare and AI.
Dmitry is a notable leader in the field of ultra-innovative technologies. He is a frequent speaker on the topic of AI and Longevity. During the last year he spoke at conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, at the Future Finance Forum in Seoul “AI in Finance” and several others at the Oxford and Cambridge Universities.
In addition to his business experience, Kaminskiy is involved in several scientific endeavors. He strongly believes in the fact that humans should live longer, healthier lives. Besides AI, Dmitry’s major interest is anti-aging and healthy longevity which he has engaged in business, research and public activities. Dmitry is well known for his support of life extension think-tanks in Oxford and Cambridge and many other non-profit activities. He is the Managing Trustee of the Biogerontology Research Foundation in Oxford, a charity expediting the coming paradigm shift from disease treatment to personalized prevention. Dmitry’s $1 million USD prize for the first person to reach their 123th birthday went viral, and was widely covered by the world’s top media.
Dmitry professes great support for the concept of BlockChain for social good, which led to his decision to support the Humaniq Bank project from its inception, which provides banking services for the world’s unbanked.
Mr. Richards is the founding partner of York Bridge Capital, a private equity firm based in Toronto, Los Angeles, and Seoul. Mr. Richards has served as a C-level executive at the aerospace investment firm Girvan Technology Holdings, the biotech firm Epigenx Biosciences Inc., the advanced materials company Antaeus Energy Corporation, and was managing director of mining and metals for the Canadian Imperial Bank of Commerce. He holds two bachelors degrees in Biology and Accounting and Finance, as well as an MBA, all from Dalhousie University. Mr. Richards is also co-founder of Tech Coast Angels (TCA), the largest angel funding network in the United States.
Reid Dabney is a seasoned financial executive, investment banker and independent management consultant. He is a founding member/Managing Director of the CFO 911 financial consulting firm, an organization of senior executives that provides accounting, finance and operational expertise to both public and private companies.
His corporate experience includes serving as a controller, treasurer and chief financial officer for private companies and public multinationals. Mr. Dabney held the positions of European Treasurer for General Foods/Philip Morris, Director of Finance for the Pillsbury Company and Assistant Treasurer for Ecolab, Inc.
His Wall Street experience encompasses nearly 15 years as a senior equity research analyst and corporate finance professional with Keefe, Bruyette & Woods, RBC Capital Markets and the BMO Financial Group. During the course of his finance career, Mr. Dabney has raised in excess of $500 million of equity and more than $2.5 billion of debt for corporate clients.
He earned a BA from Claremont McKenna College and an MBA from the University of Pennsylvania’s Wharton School. Mr. Dabney has also served on the Alumni Board of Claremont McKenna College, as the Audit Committee Chair and as a member of the Compensation Committee for ChromaDex Corporation’s Board of Directors and as an advisor for multiple start-up operations.
Marco Demaria, PhD
Dr. Demaria is a group leader at the European Research Institute for the Biology of Aging (ERIBA/UMCG) in Groningen, Netherlands. He conducted his post-doctoral research in the laboratory of Judith Campisi at the Buck Institute for Research on Aging. Marco conducted his PhD at the University of Turin on transcriptional regulation of cancer metabolism. Dr. Demaria is also a consultant for Unity Biotechnology and an editor of Nature Scientific Reports.
John Schloendorn, PhD
John is CEO of Gene and Cell Technologies. He was formerly CEO of ImmunePath, Inc. He received his PhD from the Biodesign Institute of Arizona State University. He was the director of the Institute of Biomedical Gerontology for the Methuselah Foundation. John holds a BSc from the University of Tubingen.
Emil Kendziorra, MD
Dr. Emil Kendiorra is a medical doctor and entrepreneur. He was the founder of Medlanes GmbH and OnFeedback GmbH. He received his BS from Technische Universitat Darmstadt and his M.D. from the University of Goettingen Medical School where he conducted translational cancer research. When he is not busy building companies, he is active within the geroscience research and startup communities.
Alexander Perkins is a business development analyst with core expertise in financial modeling and operations. He has served as a venture capital consultant to startups in Silicon Valley and Los Angeles, and as a political strategist for several state and national campaigns. He completed his B.A and Master's degrees in Finance at Claremont McKenna College where he was a Robert Day Scholar. He is a classically trained pianist and serves on the board of the End of Life Companions nonprofit organization.
Franco Cortese is an associate at DKLS, helping to evaluate potential portfolio companies, advising on matters of general investment strategy and establishing strategic partnerships in the for-profit and non-profit life sciences sectors. Cortese is also the Deputy Director of the Biogerontology Research Foundation, a non-profit research foundation that executes research into the basic biology of ageing and the clinical translation of biogerontological interventions for ageing and age-related disease.